These orthopedic practices paid a combined $1.85 million to settle claims that they knowingly billed state and federal health care programs for reimported osteoarthritis medications, known as viscosupplements. Viscosupplements, such as Synvisc and Orthovisc, are FDA-approved for the treatment of osteoarthritis pain in the knee and are reimbursed by Medicare, Medicaid and other federal health care programs at a set rate based on the average sales price of the domestic product. The suit alleged that these clinics knowingly purchased deeply discounted viscosupplements that had been reimported from foreign countries and billed them to state and federal health care programs, when such reimported viscosupplements were not reimbursable by those programs.